Latest news and press releases about Actinium Pharmaceuticals, Inc. (ATNM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT.
Price
| Price | $1.24 |
| Market Cap | $39M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| P/E Ratio | 4.33 |
| Price / Book | 1.62 |
| EV / EBITDA | 0.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 83.42% |
| Return on Invested Capital | 30.20% |
| Return on Assets | 28.16% |
| Gross Margin | 101.13% |
| Operating Margin | 27.23% |
| Net Margin | 32.23% |
Related companies: ANVS · FGEN · KZR · LVTX · OKUR · PDSB · RVPH
Explore sector: Healthcare · Biotechnology
More sections of ATNM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks